Why? Stanford Study of Paxlovid for Long COVID Stopped Early. Enrollment was halted earlier than planned after intern analysis. We have this from MedPage Today. No reasons were given.
Enrollment into a small trial of nirmatrelvir/ritonavir (Paxlovid) for long COVID — one that previously garnered attention for investigators not wearing masksopens in a new tab or window — has been stopped early after an interim analysis, Stanford University confirmed to MedPage Today.
Two sources familiar with the STOP-PASC studyopens in a new tab or window told MedPage Today that trial enrollment had been halted. One was told by a study coordinator that a preliminary review found “inconclusive evidence” for the primary outcome of the study. Another said their first appointment was canceled just a few days before it was supposed to take place, and they were later told that all future enrollment had been halted.
Complete article is here.
